The effect of Jinlong capsule on the immune function for intervened patients with primary liver cancer

Objective: The aim of this study was to evaluate the effect of Jinlong capsule on the immune function for intervened patients with primary liver cancer. Methods: Matched the inclusion criteria, 60 patients were selected and randomly divided into two groups. The treatment group had 30 cases treated with Jinlong capsule combined with the transcatheter arterial chemoembolization(TACE); the control group had 30 cases treated with TACE. Each group was treated 30 days as a cycle, which had completed at least two cycles. Indicators of cellular immune function about the activity of CD3, CD4, CD8, CD4/CD8 and natural killer(NK) cell were detected before and after treatment, then to compare and analysis with each other. Results: Before treatment, the activity of peripheral blood CD3, CD4, CD8, CD4/CD8 and NK cell in the two groups was no significant difference(P > 0.05); after treatment, the activity of CD3, CD4 and NK cell in the treatment group was significantly increased, the ratio of CD4/CD8 increased, and the value of CD8 decreased(P < 0.05), the activity of CD3, CD4 and NK cell in the control group was significantly decreased, the ratio of CD4/CD8 decreased(P < 0.05), and the value of CD8 slightly higher than before treatment(P > 0.05), the difference between the two groups indicated the statistical significance(P < 0.05). Incidence of gastrointestinal reactions, leucopenia, hemoglobin, platelet decline in the treatment group was lower than those in the control group, but without presenting the statistical significance(P > 0.05). Conclusion: Jinlong capsule with hepatic arterial infusion chemotherapy can improve the patients' immune function, and reduce the adverse reactions of interventional chemotherapy. Hence,it deserves to be promoted in clinically.

Jinlong capsule decreases adverse reactions after transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma

Objective The aim of this study was to analyze whether Jinlong capsule could decrease adverse reactions after transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma. Methods Eighty-two patients with hepatocellular carcinoma were randomly divided into the control group and experimental group. On the first day after TACE, the experimental group started receiving four Jinlong capsules orally three times daily, whereas the control group did not receive the treatment.Results The incidences of erythropenia and thrombocytopenia in the experimental group was lower than those in the control group(P = 0.040 and 0.033, respectively). The differences in serum levels of aminotransferase, albumin, potassium, and sodium between the two groups were significant(P = 0.034, 0.034, 0.013, and 0.044, respectively). The mean durations of stomachache and abdominal distension in the experimental group was significantly shorter than those in the control group(P = 0.004 and 0.021, respectively). However, there were no significant differences in the incidences of nausea, fever, and vomiting between the two groups(P = 0.490, 0.495, and 0.585, respectively). Conclusion The reduction in the incidence rate and duration of partial adverse reactions after TACE was observed in hepatocellular carcinoma patients treated with Jinlong capsule compared to untreated patients, suggesting possible beneficial effects exerted by Jinlong capsule on the reduction of TACE-induced liver damage, thereby improving liver function and, consequently, the quality of life.

Short-term Effect of Combined Therapy with Jinlong Capsule(金龙胶囊)and Transcatheter Arterial Chemoembolization on Patients with Primary Hepatic Carcinoma and Its Influence on Serum Osteopontin Expression

Objective：To observe the clinical combination effect of Jinlong Capsule（金龙胶囊,JLC） and transcatheter arterial chemoembolization（TACE） on the patients with primary hepatic carcinoma（PHC） and JLC＇s influence on serum osteopontin（OPN） expression and elucidate the correlation between the serum OPN level and curative effect of JLC and TACE.Methods：A total of 98 patients with PHC were observed in a randomized controlled trial（RCT）.They were assigned to the Chinese medicine（CM） group（53 patients who were treated with TACE and JLC） and the intervention group（45 patients who were treated with TACE only）.The serum OPN levels were measured before and after treatment by quantitative sandwich enzyme-linked immunosorbent assay（ELISA）.Forty healthy people were assigned to the control group.The clinical efficacy was observed and Karnofsky score（KPS） was graded.Results：The clinical efficacy of the CM group（60.38%） was better than that of the intervention group（40.00%）,and the KPS（84.35±12.19） was higher than the intervention group（69.86±11.58）（P〈0.05）.The serum OPN levels before and after treatment in the patients with PHC were significantly elevated compared with those in the control group（P〈0.01）.After treatment,the OPN levels in CM group（117.69±78.50） were significantly lower compared with those in intervention group（151.09±83.90,P〈0.05）.The OPN levels of responders were remarkably lowered than the non-responders after treatment,and the level of OPN in the CM group was lower than the intervention group（P〈0.05）.Conclusions：The short-term clinical efficacy and the quality of life of patients with PHC can be improved by combining JLC with TACE.The serum OPN levels in PHC patients can reflect the curative effect of treatment and the prognosis of the disease.

Effect of Jinlong capsule on proliferation and apoptosis of human pancreatic cancer cells BxPC-3

OBJECTIVE:To study the possible roles of Jinlong capsule(JLC) on the proliferation and apoptosis of human pancreatic cancer cells BxPC-3.METHODS:The human pancreatic cancer cells BxPC-3 were treated with JLC at the concentration of 0.05-1.00 mg/mL for 24-120 h.The inhibition rate of JLC on human pancreatic cancer cells BxPC-3 was detected by 3-(4,5-dimethiylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide(MTT) assay.Flow cytometry was employed to measure cell apoptosis using Annexin V-FITC/Propidium iodide(AV-FITC/PI) method.Cell cycles were determined by PI staining.The expression of S100 Calcium binding protein A4(S100A4) in cell matrix was measured by enzyme-linked immunosorbent assay(ELISA).The expression levels of apoptosis-related protein such as BCL2/adenovirus E1B 19 kDa interacting protein 3(BNIP3),B-cell lymphoma/leukemia-2(Bcl-2) and Cys-teinylaspartate specific proteinase 3(Caspase-3) were detected byWestern blotting.RESULTS:JLC significantly inhibited the proliferation of human pancreatic cancer cells BxPC-3 in a dose-dependent and time-dependent manner.JLC promoted cell apoptosis and maintained cell cycle in S and G 2 /M phase rather than G 1 /G 0 phase.The expression of S100A4 in the cell matrix was reduced.The expression of cell apoptotic protein BNIP3 was increased while Bcl-2 was decreased.CONCLUSION:JLC can inhibit the proliferation of human pancreatic cancer cells BxPC-3 by stimulating cell apoptosis,arresting the cell cycle at S and G 2 /M phase which blocks the circulation of normal cell cycle and reducing the expression of S100A4 protein.Higher pro-apoptosis protein BNIP3 and lower anti-apoptosis protein Bcl-2 levels were found,which may be related to the apoptotic effects of JLC.